Navigation Links
Melanoma transcriptome reveals novel genomic alterations not seen before
Date:2/22/2010

February 23, 2010 Melanoma, the most deadly form of skin cancer, afflicts more than 50,000 people in the United States annually and the incidence rate continues to rise. In a study published online in Genome Research (www.genome.org), scientists have delved deeper than ever before into the RNA world of the melanoma tumor and identified genomic alterations that could play a role in the disease.

The latest high-throughput DNA sequencing technologies are ushering in a new era of discovery in cancer genomics that promises to reveal molecular mechanisms of the disease. Beyond cataloging the genetic mutations present in tumors, application of high-throughput sequencing to the RNA "transcriptome" can uncover other genomic alterations missed by DNA sequencing and identify potential targets for therapy.

For example, two adjacent genes can be transcribed together in a single "chimeric" RNA transcript. This RNA message is then translated into a protein with an altered or new function. In addition, rearrangements of the genome can cut and paste genes together, creating "gene fusions." These events occur in normal cells, but they also have the potential to cause disease. Recently these alterations have been detected a few tumor types, and it is very likely that more will be found in other cancers such as melanoma.

To capture the full spectrum of genomic alterations present in the expressed genes of melanoma, a team of researchers in the United States and Switzerland performed an integrative analysis of melanoma tumors using RNA sequencing and structural genomic data. The group identified 11 novel gene fusions involving several common cancer-related genes, and 12 cases of chimeric transcripts. "This is the first direct evidence for these types of genetic alterations in melanoma," said Michael Berger, a research scientist at the Broad Institute and first author of the report.

A particularly interesting finding was that a recurrent chimeric transcript was found involving the CDK2 gene, known to be required for melanoma cell proliferation. The authors suggest that the functional role of the aberrant CDK2 transcript is an attractive target of future investigation. In addition to novel gene fusions and chimeric transcripts, the research group also identified many other alterations in the melanoma tumors, including novel mutations, alternative splice variants, and expression changes.

Berger noted that this type of cancer transcriptome analysis is very appealing, as it complements common DNA-based genomic sequencing and characterization approaches to capture a more complete picture of the cancer genome. "Such studies should help reveal the cancer RNA world," added Levi Garraway, an Assistant Professor at Harvard Medical School/Dana-Farber Cancer Institute and the study's senior author, "thereby nominating many new genetic targets relevant to tumor biology and drug discovery."


'/>"/>

Contact: Peggy Calicchia
calicchi@cshl.edu
516-422-4012
Cold Spring Harbor Laboratory
Source:Eurekalert

Related biology technology :

1. NYU Medical Center Collaborates With Rosetta Genomics to Develop a microRNA-Based Diagnostic Test for Melanoma
2. Reovirus Infection of Melanoma Cells Generates Anti-Tumour Immunity
3. Melanoma Research Foundation and Seattle Cancer Care Alliance Host Educational Symposium and Reception for Melanoma Patients, Family Members and Healthcare Providers
4. Genasense(R) Triple Combination Therapy in Advanced Melanoma Presented at Chemotherapy Foundation Symposium
5. DermTech Is Issued U.S. Patent for the Early Detection, Staging and Monitoring of Melanoma
6. FDA Grants Priority Review for Schering-Ploughs Peginterferon Alfa-2b for the Adjuvant Treatment of Patients With Stage III Melanoma
7. Fight Melanoma, With Joe Pesci and Dennis Haysbert on Monday, April 21st
8. DermTech Study on Melanoma Molecular Diagnostic to Be Presented at AACR
9. Oncolytics Biotech Inc. Announces Gene Therapy Publication on Reovirus Treatment for Melanoma
10. Independent Monitoring Board Recommends Completion of Accrual to Genasense(R) Phase 3 AGENDA Trial in Advanced Melanoma
11. Oncolytics Biotech Inc. Collaborators Present Reovirus and Melanoma Research at EORTC-NCI-AACR Symposium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... ... February 22, 2017 , ... ... of Tom Perkins as European director. Operating from Pennside’s Zurich headquarters, Pennside Partners, ... , Perkins joins Pennside after more than a decade with leading market research ...
(Date:2/22/2017)... SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., ... UTHR ) today announced its financial results ... 2016. "Our annual 2016 financial results ... billion and earnings exceeded $700 million," said Martine ... Officer. "These financial results strengthen our ability to ...
(Date:2/21/2017)... Inc. ("SQI" or the "Company") (TSX-V: SQD; OTCQX: SQIDF), today reported ... December 31, 2016. SQI is a ... develops and commercializes proprietary technologies and products for advanced multiplexed ... ... in fiscal 2016," said Andrew Morris , SQI,s President ...
(Date:2/21/2017)... ... February 21, 2017 , ... Vortex ... , a fully automated benchtop system for collecting intact circulating tumor cells (CTCs) ... at the Molecular Medicine Tri Conference (Tri-Con) Annual Meeting 2017 (February 19–24 San ...
Breaking Biology Technology:
(Date:2/14/2017)... WINSTON-SALEM, N.C. , Feb. 14, 2017  Wake ... FRY-shlog), M.D., as its new chief executive officer (CEO). ... succeeds CEO John D. McConnell , M.D., who ... new position at the Medical Center, after leading it ... oversee the full scope of Wake Forest Baptist,s academic ...
(Date:2/8/2017)... , Feb. 8, 2017 About Voice ... voice to match it against a stored voiceprint ... as pitch, cadence, and tone are compared to ... minimal hardware installation, as most PCs already have ... different transactions. Voice recognition biometrics are most likely ...
(Date:2/7/2017)... --  MedNet Solutions , an innovative SaaS-based eClinical technology ... is pleased to announce that the latest release of ... and award winning eClinical solution, is now available for ... a proven Software-as-a-Service (SaaS) clinical research technology platform that ... delivers an entire suite of eClinical tools to support ...
Breaking Biology News(10 mins):